Safety of granulocyte-colony-stimulating factor in acute myocardial infarction (the Rigenera study).
Leone
A M
AM
Galiuto
L
L
Rutella
S
S
Giannico
M B
MB
Brugaletta
S
S
Garramone
B
B
De Stefano
V
V
Liuzzo
G
G
Calcagni
M L
ML
Cirillo
F
F
Giordano
A
A
Niccoli
G
G
Biasucci
L M
LM
Rebuzzi
A G
AG
Leone
G
G
Crea
F
F
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D015906:Angioplasty, Balloon, Coronary; D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects; D015607:Stents; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim